Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen Phase 2 in Hyperlipoproteinemia(a) and CVD
NCT03070782Phase 2Completed
- Sponsor
- Akcea Therapeutics
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 2 trial of pelacarsen in Hyperlipoproteinemia a, cardiovascular disease (CVD), sponsored by Akcea Therapeutics. Started Mar 2017; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia acardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03070782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070782.